BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites. A new ...
RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
Freshly public BioAge Labs has secured a multiyear partnership with Novartis that focuses on age-related diseases and includes the possibility of up to $550 million in biobucks. The freshly inked deal ...
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of ...
BioAge LabsBIOA shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, a potential rival to Eli Lilly'sLLY takeover play Ventyx BiosciencesVTYX. BioAge ...
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite ...
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results